Compositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
1. A method for alleviating or treating one or more side effects of radiation comprising administering to a mammalian subject in need thereof, an effective amount of phorbol ester of Formula II, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, or polymorph thereof to said mammalian subject to alleviate or treat one or more side effects due to radiation
2. The method of claim 1 , further comprising administering at least one secondary or adjunctive therapeutic agent.
3. The method of claim 2 , wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject.
4. The method of claim 3 , wherein the at least one secondary or adjunctive therapeutic agent is selected from the group consisting of steroids, amifostine, chlorhexidine, benzydamine, sucralfate, KGF, palifermin, Cu/Zn superoxide dismutase, Interleukin 11, or prostaglandins.
5. The method of claim 1 , wherein the one or more side effects of radiation are moist desquamation, soreness, diarrhea, nausea, vomiting, appetite loss, constipation, itchy skin, peeling, mouth and throat sores, edema, infertility, fibrosis, epilation, or mucosal dryness.
6. The method of claim 1 , wherein said effective amount comprises between about 10 μg and about 1500 μg of said phorbol ester or derivative compound of Formula II every day.
7. The method of claim 6 , wherein said effective amount comprises between about 125 μg to about 500 μg of said phorbol ester or derivative compound of Formula II every day.
8. The method of claim 1 , wherein said effective amount comprises between about 10 μg and about 1500 μg of said phorbol ester or derivative compound of Formula II every other day.
9. The method of claim 8 , wherein said effective amount comprises between about 125 μg to about 500 μg of said phorbol ester or derivative compound of Formula II every other day.